Cutler Investment Counsel LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 0.2% during the 3rd quarter, Holdings Channel reports. The firm owned 61,406 shares of the company’s stock after acquiring an additional 94 shares during the period. Johnson & Johnson makes up about 1.8% of Cutler Investment Counsel LLC’s investment portfolio, making the stock its 23rd largest holding. Cutler Investment Counsel LLC’s holdings in Johnson & Johnson were worth $9,142,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Lake Point Wealth Management boosted its position in Johnson & Johnson by 144.4% in the first quarter. Lake Point Wealth Management now owns 286 shares of the company’s stock worth $38,000 after purchasing an additional 169 shares during the last quarter. Islay Capital Management LLC purchased a new position in Johnson & Johnson in the second quarter worth $42,000. FAI Wealth Management boosted its position in Johnson & Johnson by 45.9% in the second quarter. FAI Wealth Management now owns 321 shares of the company’s stock worth $45,000 after purchasing an additional 101 shares during the last quarter. SeaBridge Investment Advisors LLC boosted its position in Johnson & Johnson by 160.0% in the second quarter. SeaBridge Investment Advisors LLC now owns 325 shares of the company’s stock worth $46,000 after purchasing an additional 200 shares during the last quarter. Finally, Crewe Advisors LLC lifted its position in shares of Johnson & Johnson by 909.1% during the 3rd quarter. Crewe Advisors LLC now owns 333 shares of the company’s stock valued at $50,000 after buying an additional 300 shares during the last quarter. 67.44% of the stock is currently owned by institutional investors and hedge funds.

Shares of NYSE:JNJ traded up $0.91 during midday trading on Friday, reaching $148.10. 6,098,404 shares of the company traded hands, compared to its average volume of 8,259,329. The company has a quick ratio of 0.99, a current ratio of 1.25 and a debt-to-equity ratio of 0.40. Johnson & Johnson has a 12 month low of $109.16 and a 12 month high of $157.00. The firm has a market capitalization of $389.92 billion, a price-to-earnings ratio of 23.29, a price-to-earnings-growth ratio of 3.36 and a beta of 0.68. The firm’s fifty day moving average price is $148.57 and its two-hundred day moving average price is $146.59.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Sunday, October 18th. The company reported $2.20 earnings per share for the quarter, topping analysts’ consensus estimates of $1.98 by $0.22. The business had revenue of $21.08 billion for the quarter, compared to analyst estimates of $20.15 billion. Johnson & Johnson had a return on equity of 35.21% and a net margin of 22.69%. The company’s quarterly revenue was up 1.7% compared to the same quarter last year. During the same period in the prior year, the company earned $2.12 EPS. Analysts forecast that Johnson & Johnson will post 8 earnings per share for the current year.

A number of brokerages have recently commented on JNJ. Citigroup upped their price target on Johnson & Johnson from $165.00 to $170.00 and gave the company a “buy” rating in a research report on Friday, July 17th. Cantor Fitzgerald upped their price target on Johnson & Johnson from $168.00 to $180.00 and gave the company an “overweight” rating in a research report on Wednesday. ValuEngine raised Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Monday, August 3rd. Credit Suisse Group upped their price target on Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a research report on Wednesday. Finally, Raymond James upped their price target on Johnson & Johnson from $157.00 to $158.00 and gave the company an “outperform” rating in a research report on Friday, July 17th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and ten have assigned a buy rating to the company. Johnson & Johnson currently has an average rating of “Buy” and an average price target of $164.93.

In other Johnson & Johnson news, EVP Ashley Mcevoy sold 29,000 shares of the company’s stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $147.47, for a total value of $4,276,630.00. Following the transaction, the executive vice president now directly owns 21,682 shares in the company, valued at approximately $3,197,444.54. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Kathryn E. Wengel sold 16,115 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total value of $2,473,974.80. Following the completion of the transaction, the executive vice president now owns 66,658 shares in the company, valued at $10,233,336.16. The disclosure for this sale can be found here. 0.27% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Article: What is the Consumer Price Index (CPI)?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.